| ID | Sequence | Length | GC content |
|---|---|---|---|
| GAGCUCGGCUCUUGAGACAGGAAUCUUGCCCAUUCCCCGAACGAAUAAA… | 553 nt | 0.5497 | |
| GAGCUCGGCUCUUGAGACAGGAAUCUUGCCCAUUCCCCGAACGAAUAAA… | 615 nt | 0.5545 | |
| CCUGAUAAAGGUCCUGCGGGCAGGACAGGACCUCCCAACCAAGCCCUCC… | 595 nt | 0.5529 | |
| AGGCGGUCAGGGGAAGGCUCAGGAGGAGGGAGAUCAACAUCAACCUGCC… | 514 nt | 0.5778 |
This gene encodes a member of the apolipoprotein C1 family. This gene is expressed primarily in the liver, and it is activated when monocytes differentiate into macrophages. The encoded protein plays a central role in high density lipoprotein (HDL) and very low density lipoprotein (VLDL) metabolism. This protein has also been shown to inhibit cholesteryl ester transfer protein in plasma. A pseudogene of this gene is located 4 kb downstream in the same orientation, on the same chromosome. This gene is mapped to chromosome 19, where it resides within a apolipoprotein gene cluster. Alternative splicing and the use of alternative promoters results in multiple transcript variants. [provided by RefSeq, Sep 2016]
A study in human blood plasma demonstrated that the APOC1 is a protein significantly downregulated with age, and it was used alongside other proteins and small RNAs to build age-predictive models, with a combined proteomic and miRNA model achieving an R² of 0.70 ± 0.01 [Salignon et al. DOI:10.18632/aging.204787]. In human corpus cavernosum tissue, the APOC1 was identified as a gene marker defining the APOC1+ fibroblast subclusters FB1 and FB2, with its expression pattern used to classify cellular heterogeneity [Zhao et al. DOI:10.1038/s41467-022-31950-9].